{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:54:48Z","timestamp":1770832488191,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-156007"],"award-info":[{"award-number":["PJT-156007"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD104553"],"award-info":[{"award-number":["R01HD104553"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre for Blood Research Graduate Award"},{"name":"British Columbia Graduate Scholarship"},{"name":"CIHR Doctoral Research Award"},{"name":"CIHR Canadian HIV Trials Network"},{"name":"CIHR Postdoctoral Fellowships"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Each year, approximately 1.1 million children are exposed in utero to human immunodeficiency virus antiretrovirals, yet their safety is often not well characterized during pregnancy. The Tsepamo study reported a neural tube defect signal in infants exposed to the integrase strand transfer inhibitor (InSTI) dolutegravir from conception, suggesting that exposure during early fetal development may be detrimental<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The effects of InSTIs on 2 human embryonic stem cell (hESC) lines were characterized with respect to markers of pluripotency, early differentiation, and cellular health. In addition, fetal resorptions after exposure to InSTIs from conception were analyzed in pregnant mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At subtherapeutic concentrations, second-generation InSTIs bictegravir, cabotegravir, and dolutegravir decreased hESC counts and pluripotency and induced dysregulation of genes involved in early differentiation. At therapeutic concentrations, bictegravir induced substantial hESC death and fetal resorptions. It is notable that first-generation InSTI raltegravir did not induce any hESC toxicity or differentiation, at any concentration tested.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Exposure to some InSTIs, even at subtherapeutic concentrations, can induce adverse effects in hESCs and pregnant mice. Given the increasingly prevalent use of second-generation InSTIs, including in women of reproductive age, it is imperative to further elucidate the effect of InSTIs on embryonic development, as well as their long-term safety after in utero exposure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac386","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T09:48:02Z","timestamp":1663667282000},"page":"1992-2001","source":"Crossref","is-referenced-by-count":11,"title":["Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse Models"],"prefix":"10.1093","volume":"226","author":[{"given":"Marie-Soleil R","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Blood Research, University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haneesha","family":"Mohan","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Ajaykumar","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Blood Research, University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony Y Y","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Blood Research, University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lou","family":"Martineau","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronil","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabella","family":"Gadawska","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Blood Research, University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sherwood","sequence":"additional","affiliation":[{"name":"Michael Smith Laboratories, University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-6134","authenticated-orcid":false,"given":"Lena","family":"Serghides","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network , Toronto , Canada"},{"name":"Department of Immunology and Institute of Medical Sciences, University of Toronto , Toronto, Ontario , Canada"},{"name":"Women\u2019s College Research Institute , Toronto , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Piret","sequence":"additional","affiliation":[{"name":"Michael Smith Laboratories, University of British Columbia , Vancouver , Canada"},{"name":"Department of Chemical and Biological Engineering, University of British Columbia , Vancouver , Canada"},{"name":"School of Biomedical Engineering, The University of British Columbia , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne C F","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver , Canada"},{"name":"Centre for Blood Research, University of British Columbia , Vancouver , Canada"},{"name":"Women\u2019s Health Research Institute , Vancouver , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"2023060109493221200_jiac386-B1","author":"UNAIDS","year":"2020"},{"key":"2023060109493221200_jiac386-B2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S2055-6640(20)30247-8","article-title":"Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review","volume":"4","author":"Hill","year":"2018","journal-title":"J Virus Erad"},{"key":"2023060109493221200_jiac386-B3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/1471-0528.15864","article-title":"What will it take to refute the possible safety signal for dolutegravir and neural tube defects?","volume":"126","author":"Zash","year":"2019","journal-title":"BJOG-Int J Obstet Gy"},{"key":"2023060109493221200_jiac386-B4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s40506-019-00203-7","article-title":"Update on adverse effects of HIV integrase inhibitors","volume":"11","author":"Kolakowska","year":"2019","journal-title":"Curr Treat Options Infect Dis"},{"key":"2023060109493221200_jiac386-B5","article-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization","year":"2019"},{"key":"2023060109493221200_jiac386-B6","author":"Panel on Treatment of HIV during Pregnancy and Prevention of Perinatal Transmission","year":"2021"},{"key":"2023060109493221200_jiac386-B7","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3018(20)30038-2","article-title":"Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial","volume":"7","author":"Jo\u00e3o","year":"2020","journal-title":"Lancet HIV"},{"key":"2023060109493221200_jiac386-B8","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","article-title":"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010\/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"key":"2023060109493221200_jiac386-B9","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1097\/QAD.0000000000001992","article-title":"Elvitegravir\/cobicistat pharmacokinetics in pregnant and postpartum women with HIV","volume":"32","author":"Momper","year":"2018","journal-title":"AIDS"},{"key":"2023060109493221200_jiac386-B10","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1093\/cid\/ciaa488","article-title":"Clinically significant lower elvitegravir exposure during the third trimester of pregnant patients living with human immunodeficiency virus: data from the pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) network","volume":"71","author":"Bukkems","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023060109493221200_jiac386-B11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/QAD.0000000000002637","article-title":"Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model","volume":"34","author":"Pencol\u00e9","year":"2020","journal-title":"AIDS"},{"key":"2023060109493221200_jiac386-B12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N Engl J Med"},{"key":"2023060109493221200_jiac386-B13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-Tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N Engl J Med"},{"key":"2023060109493221200_jiac386-B14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/1471-0528.15838","article-title":"Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study","volume":"126","author":"Money","year":"2019","journal-title":"BJOG-Int J Obstet Gy"},{"key":"2023060109493221200_jiac386-B15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/QAI.0000000000002035","article-title":"Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir","volume":"81","author":"Vannappagari","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023060109493221200_jiac386-B16","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2352-3018(20)30268-X","article-title":"Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study","volume":"8","author":"Pereira","year":"2021","journal-title":"Lancet HIV"},{"key":"2023060109493221200_jiac386-B17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151586","article-title":"Describing the prevalence of neural tube defects worldwide: a systematic literature review","volume":"11","author":"Zaganjor","year":"2016","journal-title":"PloS One"},{"key":"2023060109493221200_jiac386-B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103167","article-title":"Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels","volume":"63","author":"Mohan","year":"2021","journal-title":"EBioMedicine"},{"key":"2023060109493221200_jiac386-B19","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/QAD.0000000000002289","article-title":"The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid","volume":"33","author":"Cabrera","year":"2019","journal-title":"AIDS"},{"key":"2023060109493221200_jiac386-B20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1124\/dmd.119.087635","article-title":"Clinical extrapolation of the effects of dolutegravir and other HIV integrase inhibitors on folate transport pathways","volume":"47","author":"Zamek-Gliszczynski","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"2023060109493221200_jiac386-B21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/toxsci\/kfab112","article-title":"Dolutegravir impairs stem cell-based 3D morphogenesis models in a manner dependent on dose and timing of exposure: an implication for its developmental toxicity","volume":"184","author":"Kirkwood-Johnson","year":"2021","journal-title":"Toxicol Sci"},{"key":"2023060109493221200_jiac386-B22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103771","article-title":"Interaction between dolutegravir and folate transporters and receptor in human and rodent placenta","volume":"75","author":"Gilmore","year":"2022","journal-title":"EBioMedicine"},{"key":"2023060109493221200_jiac386-B23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.taap.2010.05.007","article-title":"Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics","volume":"247","author":"West","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"2023060109493221200_jiac386-B24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1039\/c8ib00082d","article-title":"Teratogen screening with human pluripotent stem cells","volume":"10","author":"Worley","year":"2018","journal-title":"Integr Biol (Camb)"},{"key":"2023060109493221200_jiac386-B25","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2174\/1381612826666201019104712","article-title":"Stem cell based preclinical drug development and toxicity prediction","volume":"27","author":"Kumar","year":"2021","journal-title":"Curr Pharm Des"},{"key":"2023060109493221200_jiac386-B26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/bdr2.1949","article-title":"No developmental toxicity observed with dolutegravir in rat whole embryo culture","volume":"113","author":"Posobiec","year":"2021","journal-title":"Birth Defects Res"},{"key":"2023060109493221200_jiac386-B27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/bdr2.1969","article-title":"Dolutegravir and rat whole embryo culture","volume":"114","author":"Copp","year":"2021","journal-title":"Birth Defects Res"},{"key":"2023060109493221200_jiac386-B28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"2023060109493221200_jiac386-B29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2018.09.008","article-title":"Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens","volume":"159","author":"Kala","year":"2018","journal-title":"Antiviral Res"},{"key":"2023060109493221200_jiac386-B30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/pharmaceutics14051063","article-title":"Comparison of the effects of three dual-nucleos(t)ide reverse transcriptase inhibitor backbones on placenta mitochondria toxicity and oxidative stress using a mouse pregnancy model","volume":"14","author":"Balogun","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023060109493221200_jiac386-B31","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/QAD.0000000000002550","article-title":"Safety of in utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected","volume":"34","author":"Crowell","year":"2020","journal-title":"AIDS"},{"key":"2023060109493221200_jiac386-B32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"key":"2023060109493221200_jiac386-B33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00204-011-0782-2","article-title":"Diverse effects of dimethyl sulfoxide (DMSO) on the differentiation potential of human embryonic stem cells","volume":"86","author":"Pal","year":"2012","journal-title":"Arch Toxicol"},{"key":"2023060109493221200_jiac386-B34","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/bit.24936","article-title":"A human embryonic stem cell line adapted for high throughput screening","volume":"110","author":"Caron","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"2023060109493221200_jiac386-B35","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/00016340802428146","article-title":"Reference values for \u03b11-acid glycoprotein, \u03b11-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy","volume":"87","author":"Larsson","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2023060109493221200_jiac386-B36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220323","article-title":"Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model","volume":"14","author":"Mandelbrot","year":"2019","journal-title":"Plos One"},{"key":"2023060109493221200_jiac386-B37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/clinchem\/44.3.683","article-title":"Reference intervals for 18 clinical chemistry analytes in fetal plasma samples between 18 and 40 weeks of pregnancy","volume":"44","author":"Gozzo","year":"1998","journal-title":"Clin Chem"},{"key":"2023060109493221200_jiac386-B38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/AOG.0b013e31816a49e2","article-title":"Bilirubin\/albumin ratios in fetal blood and in amniotic fluid in rhesus immunization","volume":"111","author":"Pasman","year":"2008","journal-title":"Obstet Gynecol"},{"key":"2023060109493221200_jiac386-B39","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac386\/46381758\/jiac386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/11\/1992\/50499234\/jiac386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/11\/1992\/50499234\/jiac386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:51:03Z","timestamp":1685613063000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/11\/1992\/6704757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,19]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac386","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,9,19]]}}}